Marketing authorisation holders are advised to submit any type IB variations or groupings of type IBs and type IAs by 3rd December 2021 for a start of procedure in 2021
Its unique technology, ChetoSensar gives new promise to ADCs by alleviating solubility challenges
Two leaders in science combine complementary best-in-class technologies for biologics manufacturing customers
It launched the most advanced "DTAS" (Direct to Angio Suite) & State of the art ‘Neuro-Angio’ technology
Acute therapies continue to report strong growth compared to chronic ones.
In India, MSD has signed non-exclusive licensing agreements with eight pharma companies.
The Phase 3 study is designed to bridge data collected from the vaccine efficacy trial conducted in India to the U.S. population
The collaboration aims to deliver greater insights to the oncology fraternity, predict patient therapy responses and enable therapy selection resulting in optimal treatment outcomes.
It answers the most basic questions from a patient’s perspective
Subscribe To Our Newsletter & Stay Updated
